Manufacturing Viral Vectors for the Next Phase of CGT
As the sector matures, scalable vector production and robust analytical control are becoming essential to clinical and commercial success
False
As the sector matures, scalable vector production and robust analytical control are becoming essential to clinical and commercial success
False
False
November 7, 2014
0 min read
Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.
April 2, 2025
5 min read
Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.
April 1, 2025
3 min read
Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”
April 1, 2025
9 min read
Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.
False
Affiliations:
Specialties:
Areas of Expertise: